Another study (NCT04201457) is exploring the use of hydroxychloroquine in combination with trametinib (for BRAF fusion or NF-1 associated glioma) or with trametinib and dabrafenib (for BRAFp.V600E) in recurrent pLGGs or pHGGs). This evidence concerns the gene NF1 and central nervous system cancer.